Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 7, 2008, Pages 741-747

  Chen, Andy I ^a   McMillan, Alex ^a   Negrin, Robert S ^a   Horning, Sandra J ^a   Laport, Ginna G ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous transplantation; Lymphoma; Peripheral T cell lymphoma

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; RELAPSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL TIME; T CELL LEUKEMIA; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTE DEPLETION; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 44649140596     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.004     Document Type: Article

References (27)

1. Vose J.M. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 106 (2005) a811
2. Kewalramani T., Zelenetz A.D., Teruya-Feldstein J., et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134 (2006) 202-207
3. Smith S.D., Bolwell B.J., Rybicki L.A., et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 40 (2007) 239-243
4. Rodriguez J., Conde E., Gutierrez A., et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92 (2007) 1067-1074
5. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20 (2006) 1533-1538
6. Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79 (2007) 32-38
7. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
8. Negrin R.S., Kusnierz-Glaz C.R., Still B.J., et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 85 (1995) 3334-3341
9. Dreger P., Viehmann K., von Neuhoff N., et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant 24 (1999) 153-161
10. Law L.Y., Horning S.J., Wong R.M., et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 12 (2006) 703-711
11. Nademanee A.P., Zain J.M., Palmer J., et al. The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-cell lymphoma (PTCL). Blood 108 (2006) a3060
12. Jagasia M., Morgan D., Goodman S., et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45 (2004) 2261-2267
13. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18 (2007) 652-657
14. Yang D.-H., Kim W.S., Kim S.J., et al. The clinical outcomes of autologous stem cell transplantation in peripheral T cell lymphoma: from Retrospective Multicenter Study in Korea. Blood 110 (2007) a1892
15. Reimer P., Schertlin T., Rudiger T., et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 5 (2004) 304-311
16. Blystad A.K., Enblad G., Kvaloy S., et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27 (2001) 711-716
17. Feyler S., Prince H.M., Pearce R., et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 40 (2007) 443-450
18. Song K.W., Mollee P., Keating A., and Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 120 (2003) 978-985
19. Kim M.K., Kim S., Lee S.S., et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 86 (2007) 435-442
20. Advani R., Hymes K., Pohlman B., et al. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a phase II study. Blood 110 (2007) a3453
21. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136 (2007) 439-447
22. Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103 (2004) 2920-2924
23. O'Connor O.A., Hamlin P.A., Gerecitano J., et al. Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC Phase I/II experience. Blood 108 (2006) a400
24. Gisselbrecht C., Gaulard P., Lepage E., et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92 (1998) 76-82
25. Went P., Agostinelli C., Gallamini A., et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24 (2006) 2472-2479
26. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004) 2172-2176
27. Coleman C.N., Picozzi Jr. V.J., Cox R.S., et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4 (1986) 1628-1637